Global Erectile Dysfunction Drugs Market, By Drug Type (Sildenafil Citrate (Viagra), Vardenafil (Levitra/ Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Lodenafil Carbonate (Helleva), Stendra/ Spedra (Avanafil), Mirodenafil (Mvix), Others), Mode of Administration (Oral Medications, Topical Medications, Injections, Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights of Erectile Dysfunction Drugs
Erectile dysfunction drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 547.57 million by 2028 and will grow at a CAGR of 5.22% in the above mentioned forecast period.
Erectile dysfunction is defined as unrelenting difficulty achieving and maintaining an erection sufficient to have sex. Erectile dysfunction is largely caused by chronic diseases resulting from sedentary lifestyle such as obesity, cardiovascular diseases, diabetes and high blood pressure.
The high adoption of a sedentary lifestyle and rising incidence of lifestyle diseases is amongst the important factors intensifying the growth and demand of erectile dysfunction drugs market. In addition, the rapidly increasing geriatric population and rapid increase in patient awareness and education levels are also contributing to the growth in the global market over the forecast period of 2021 to 2028. Also the various government reforms and public awareness initiatives in developing regions are also enhancing the growth of the market. Likewise, the rising manufactures of generic drugs associated with increasing adoption of a sedentary lifestyle along with the associated stress is also lifting the market growth in the above mentioned forecast period. Also, the rising number of men suffering from this disorder and patent expiry of number of blockbuster drugs are also one of the significant factors fueling the growth of the erectile dysfunction drugs market.
The rising investments in R&D for the development of new drugs and clinical trials will further accelerate the expansion of the erectile dysfunction drugs market and are also are offering significant growth opportunities for the market in the forecast period of 2021 to 2028.
However, the poor patient adherence to erectile dysfunction drug, and availability of cost-effective counterfeit drugs will curb the growth of the erectile dysfunction drugs market, whereas the various side effects coupled with this drug have the potential to challenge the growth of the erectile dysfunction drugs market.
This erectile dysfunction drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on erectile dysfunction drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Erectile Dysfunction Drugs Market Scope and Market Size
Erectile dysfunction drugs market is segmented on the basis of drug type, mode of administration and end user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of product type, the erectile dysfunction drugs market is segmented into sildenafil citrate (viagra), vardenafil (levitra/ staxyn), tadalafil (cialis), udenafil (zydena), lodenafil carbonate (helleva), stendra/ spedra (avanafil), mirodenafil (mvix) and others.
- On the basis of mode of administration, the erectile dysfunction drugs market is segmented into oral medications, topical medications, injections and others.
- The end user segment of erectile dysfunction drugs market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Erectile Dysfunction Drugs Market Country Level Analysis
Erectile dysfunction drugs market is analyzed and market size insights and trends are provided by country, drug type, mode of administration and end user as referenced above.
The countries covered in the erectile dysfunction drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.
North America region leads the erectile dysfunction drugs market owing to the strong presence of an established healthcare infrastructure, increasing demand for erectile dysfunction drugs and increasing R&D initiatives pertaining to the development of new drug molecules within the region. Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2021 to 2028 because of the increasing prevalence of erectile dysfunction causing infections, rising base of geriatric population and thriving generic drugs industry in this particular region.
The country section of the erectile dysfunction drugs market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Erectile dysfunction drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for erectile dysfunction drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the erectile dysfunction drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Erectile Dysfunction Drugs Market Share Analysis
Erectile dysfunction drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to erectile dysfunction drugs market.
The major players covered in the erectile dysfunction drugs market report are Bayer AG, VIVUS Inc., LUPIN, Boston Scientific Corporation, Coloplast Corp, Teva Pharmaceutical Industries Ltd., Metuchen Pharmaceuticals, LLC., Ferring B.V., Zydus Cadila, GlaxoSmithKline Plc., Eli Lilly and Company, Varah Healthcare, Alpha Pharmaceuticals, Pfizer Inc., and Actiza Pharmaceutical Private Limited among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
